Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: Results from a multicentre prospective study

Cosimo De Nunzio, Giuseppe Simone, Aldo Brassetti, Riccardo Mastroianni, Devis Collura, Giovanni Muto, Michele Gallucci, Andrea Tubaro

Research output: Contribution to journalArticle

Abstract

Background: Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk factors are age, race and family history. A possible association between metabolic syndrome (MetS) and PCa was firstly described in 2004 and several subsequent studies in biopsy cohorts have shown conflicting results. Aim of our multicentre prospective study was to investigate the association between MetS and PCa in men undergoing radical prostatectomy (RP). Methods: From January 2012 to June 2015, 349 consecutive men undergoing RP for PCa at three centres in Italy were enrolled into a prospective database. Body Mass Index (BMI) as well as waist circumference was measured before RP. Blood samples were also collected and tested for total PSA, fasting glucose, triglycerides and HDLs. Blood pressure was also recorded. We evaluated the association between MetS, defined according to Adult Treatment Panel III, PCa stage (advanced stage defined as pT ≥ 3 or N1) and grade (high grade defined as Gleason Score ≥ 4 + 3) using logistic regression analyses. Results: Median age and preoperative PSA levels were 66 years (IQR: 61-69) and 7 ng/ml (IQR: 5-10), respectively. Median BMI was 26.12 kg/m2 (IQR 24-29) with 56 (16 %) obese (BMI ≥ 30 kg/m2) patients and 87 (25 %) patients with MetS. At pathological evaluation, advanced PCa and high-grade disease were present in 126 (36 %) and 145 (41.5 %) patients, respectively. MetS was significantly associated with advanced PCa (45/87, 51 % vs 81/262, 31 %; p = 0.008) and high-grade disease (47/87, 54 % vs 98/262, 37 %; p = 0.001). On multivariable analysis, MetS was an independent predictor of pathological stage ≥ pT3a or N1 (OR: 2.227; CI: 1.273-3.893; p = 0.005) and Gleason score ≥ 4 + 3 (OR: 2.007, CI: 1.175-3.428; p = 0.011). Conclusions: We firstly demonstrated in a European radical retropubic prostatectomy cohort study that MetS is associated with an increased risk of high-grade and advanced prostate cancer. Further studies with long term follow-up should evaluate the impact of Mets on PCa survival.

Original languageEnglish
Article number407
JournalBMC Cancer
Volume16
Issue number1
DOIs
Publication statusPublished - Jul 7 2016

Fingerprint

Prostatectomy
Multicenter Studies
Prostatic Neoplasms
Prospective Studies
Body Mass Index
Neoplasm Grading
Waist Circumference
Italy
Cause of Death
Fasting
Neoplasms
Triglycerides
Cohort Studies
Logistic Models
Regression Analysis
Databases
Blood Pressure
Biopsy
Glucose
Survival

Keywords

  • High grade
  • Metabolic syndrome
  • Prostate
  • Prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Cite this

Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy : Results from a multicentre prospective study. / De Nunzio, Cosimo; Simone, Giuseppe; Brassetti, Aldo; Mastroianni, Riccardo; Collura, Devis; Muto, Giovanni; Gallucci, Michele; Tubaro, Andrea.

In: BMC Cancer, Vol. 16, No. 1, 407, 07.07.2016.

Research output: Contribution to journalArticle

De Nunzio, Cosimo ; Simone, Giuseppe ; Brassetti, Aldo ; Mastroianni, Riccardo ; Collura, Devis ; Muto, Giovanni ; Gallucci, Michele ; Tubaro, Andrea. / Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy : Results from a multicentre prospective study. In: BMC Cancer. 2016 ; Vol. 16, No. 1.
@article{7499f698b17747f6920ceb1dee78d101,
title = "Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy: Results from a multicentre prospective study",
abstract = "Background: Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk factors are age, race and family history. A possible association between metabolic syndrome (MetS) and PCa was firstly described in 2004 and several subsequent studies in biopsy cohorts have shown conflicting results. Aim of our multicentre prospective study was to investigate the association between MetS and PCa in men undergoing radical prostatectomy (RP). Methods: From January 2012 to June 2015, 349 consecutive men undergoing RP for PCa at three centres in Italy were enrolled into a prospective database. Body Mass Index (BMI) as well as waist circumference was measured before RP. Blood samples were also collected and tested for total PSA, fasting glucose, triglycerides and HDLs. Blood pressure was also recorded. We evaluated the association between MetS, defined according to Adult Treatment Panel III, PCa stage (advanced stage defined as pT ≥ 3 or N1) and grade (high grade defined as Gleason Score ≥ 4 + 3) using logistic regression analyses. Results: Median age and preoperative PSA levels were 66 years (IQR: 61-69) and 7 ng/ml (IQR: 5-10), respectively. Median BMI was 26.12 kg/m2 (IQR 24-29) with 56 (16 {\%}) obese (BMI ≥ 30 kg/m2) patients and 87 (25 {\%}) patients with MetS. At pathological evaluation, advanced PCa and high-grade disease were present in 126 (36 {\%}) and 145 (41.5 {\%}) patients, respectively. MetS was significantly associated with advanced PCa (45/87, 51 {\%} vs 81/262, 31 {\%}; p = 0.008) and high-grade disease (47/87, 54 {\%} vs 98/262, 37 {\%}; p = 0.001). On multivariable analysis, MetS was an independent predictor of pathological stage ≥ pT3a or N1 (OR: 2.227; CI: 1.273-3.893; p = 0.005) and Gleason score ≥ 4 + 3 (OR: 2.007, CI: 1.175-3.428; p = 0.011). Conclusions: We firstly demonstrated in a European radical retropubic prostatectomy cohort study that MetS is associated with an increased risk of high-grade and advanced prostate cancer. Further studies with long term follow-up should evaluate the impact of Mets on PCa survival.",
keywords = "High grade, Metabolic syndrome, Prostate, Prostate cancer",
author = "{De Nunzio}, Cosimo and Giuseppe Simone and Aldo Brassetti and Riccardo Mastroianni and Devis Collura and Giovanni Muto and Michele Gallucci and Andrea Tubaro",
note = "Giuseppe SIMONE in doppia affiliazione",
year = "2016",
month = "7",
day = "7",
doi = "10.1186/s12885-016-2442-7",
language = "English",
volume = "16",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Metabolic syndrome is associated with advanced prostate cancer in patients treated with radical retropubic prostatectomy

T2 - Results from a multicentre prospective study

AU - De Nunzio, Cosimo

AU - Simone, Giuseppe

AU - Brassetti, Aldo

AU - Mastroianni, Riccardo

AU - Collura, Devis

AU - Muto, Giovanni

AU - Gallucci, Michele

AU - Tubaro, Andrea

N1 - Giuseppe SIMONE in doppia affiliazione

PY - 2016/7/7

Y1 - 2016/7/7

N2 - Background: Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk factors are age, race and family history. A possible association between metabolic syndrome (MetS) and PCa was firstly described in 2004 and several subsequent studies in biopsy cohorts have shown conflicting results. Aim of our multicentre prospective study was to investigate the association between MetS and PCa in men undergoing radical prostatectomy (RP). Methods: From January 2012 to June 2015, 349 consecutive men undergoing RP for PCa at three centres in Italy were enrolled into a prospective database. Body Mass Index (BMI) as well as waist circumference was measured before RP. Blood samples were also collected and tested for total PSA, fasting glucose, triglycerides and HDLs. Blood pressure was also recorded. We evaluated the association between MetS, defined according to Adult Treatment Panel III, PCa stage (advanced stage defined as pT ≥ 3 or N1) and grade (high grade defined as Gleason Score ≥ 4 + 3) using logistic regression analyses. Results: Median age and preoperative PSA levels were 66 years (IQR: 61-69) and 7 ng/ml (IQR: 5-10), respectively. Median BMI was 26.12 kg/m2 (IQR 24-29) with 56 (16 %) obese (BMI ≥ 30 kg/m2) patients and 87 (25 %) patients with MetS. At pathological evaluation, advanced PCa and high-grade disease were present in 126 (36 %) and 145 (41.5 %) patients, respectively. MetS was significantly associated with advanced PCa (45/87, 51 % vs 81/262, 31 %; p = 0.008) and high-grade disease (47/87, 54 % vs 98/262, 37 %; p = 0.001). On multivariable analysis, MetS was an independent predictor of pathological stage ≥ pT3a or N1 (OR: 2.227; CI: 1.273-3.893; p = 0.005) and Gleason score ≥ 4 + 3 (OR: 2.007, CI: 1.175-3.428; p = 0.011). Conclusions: We firstly demonstrated in a European radical retropubic prostatectomy cohort study that MetS is associated with an increased risk of high-grade and advanced prostate cancer. Further studies with long term follow-up should evaluate the impact of Mets on PCa survival.

AB - Background: Prostate cancer (PCa) is the most common non-skin cancer in USA and the second leading cause of cancer death in Western Countries. Despite the high mortality associated with PCa, the only established risk factors are age, race and family history. A possible association between metabolic syndrome (MetS) and PCa was firstly described in 2004 and several subsequent studies in biopsy cohorts have shown conflicting results. Aim of our multicentre prospective study was to investigate the association between MetS and PCa in men undergoing radical prostatectomy (RP). Methods: From January 2012 to June 2015, 349 consecutive men undergoing RP for PCa at three centres in Italy were enrolled into a prospective database. Body Mass Index (BMI) as well as waist circumference was measured before RP. Blood samples were also collected and tested for total PSA, fasting glucose, triglycerides and HDLs. Blood pressure was also recorded. We evaluated the association between MetS, defined according to Adult Treatment Panel III, PCa stage (advanced stage defined as pT ≥ 3 or N1) and grade (high grade defined as Gleason Score ≥ 4 + 3) using logistic regression analyses. Results: Median age and preoperative PSA levels were 66 years (IQR: 61-69) and 7 ng/ml (IQR: 5-10), respectively. Median BMI was 26.12 kg/m2 (IQR 24-29) with 56 (16 %) obese (BMI ≥ 30 kg/m2) patients and 87 (25 %) patients with MetS. At pathological evaluation, advanced PCa and high-grade disease were present in 126 (36 %) and 145 (41.5 %) patients, respectively. MetS was significantly associated with advanced PCa (45/87, 51 % vs 81/262, 31 %; p = 0.008) and high-grade disease (47/87, 54 % vs 98/262, 37 %; p = 0.001). On multivariable analysis, MetS was an independent predictor of pathological stage ≥ pT3a or N1 (OR: 2.227; CI: 1.273-3.893; p = 0.005) and Gleason score ≥ 4 + 3 (OR: 2.007, CI: 1.175-3.428; p = 0.011). Conclusions: We firstly demonstrated in a European radical retropubic prostatectomy cohort study that MetS is associated with an increased risk of high-grade and advanced prostate cancer. Further studies with long term follow-up should evaluate the impact of Mets on PCa survival.

KW - High grade

KW - Metabolic syndrome

KW - Prostate

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84977570863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977570863&partnerID=8YFLogxK

U2 - 10.1186/s12885-016-2442-7

DO - 10.1186/s12885-016-2442-7

M3 - Article

AN - SCOPUS:84977570863

VL - 16

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 407

ER -